Drug on the Market

Available for over a year

Every 72 seconds a new patient is diagnosed with Alzheimer’s disease and it’s estimated by 2050 healthcare costs will be around $1 trillion, a big worry in a world with an ageing population. In this week’s Global Business Peter Day hears from Dr. Andrea Pfeifer of the Swiss biotech company, AC Immune and hears how this small company is making encouraging strides in it’s quest for effective treatments for Alzheimer’s Disease.